Alnylam Pharmaceuticals' Other Working Capital Changes fell 300.64% to -$12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$65.8 million, marking a year-over-year increase of 67.92%. This contributed to the annual value of -$235.4 million for FY2024, which is 527.91% down from last year.
Alnylam Pharmaceuticals' Other Working Capital Changes amounted to -$235.4 million in FY2024, which was down 527.91% from $55.0 million recorded in FY2023.
Alnylam Pharmaceuticals' 5-year Other Working Capital Changes high stood at $55.0 million for FY2023, and its period low was -$235.4 million during FY2024.
Over the past 3 years, Alnylam Pharmaceuticals' median Other Working Capital Changes value was -$65.9 million (recorded in 2022), while the average stood at -$82.1 million.
Per our database at Business Quant, Alnylam Pharmaceuticals' Other Working Capital Changes spiked by 183.48% in 2023 and then crashed by 527.91% in 2024.
Yearly analysis of 5 years shows Alnylam Pharmaceuticals' Other Working Capital Changes stood at -$44.0 million in 2020, then fell by 14.65% to -$50.4 million in 2021, then slumped by 30.77% to -$65.9 million in 2022, then skyrocketed by 183.48% to $55.0 million in 2023, then tumbled by 527.91% to -$235.4 million in 2024.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value